It's as easy as 1-2-3
Sep 12, 2022 HeartBeat.bio AG, a biotech company developing cardiac organoids (Cardioids), have entered into a co-development agreement to commercialize production of Cardioids and will be compatible with Molecular Devices’ Organoid Innovation Center solutions available today.
Visit the OIC
Read press release
Learn how scientists are advancing discovery with our products and solutions.
SpectraNet is an intuitive, simple-to-use, self-service customer portal providing a new level of experience available 24/7.
Create your account today to get full access to integrated content and world-class customer service.
Oct 12, 2022 Larger site will be future home of the Organoid Innovation Center – Salzburg, a collaborative space for advancing automated cell line development, organoid development, and screening solutions to improve drug discovery
Providing our customers with innovative bioanalytical solutions for protein and cell biology for over 30 years.
Our team-oriented corporate culture ensures diversity of thought, perspective, and a strong relationship of trust.
In September, the U.S. Senate unanimously passed the FDA Modernization Act 2.0, which would lift an 84-year-old federal mandate for animal testing for toxicity studies. While the bill doesn’t ban animal testing outright, it would allow drug developers to use alternatives when feasible.
To learn more about these alternatives, Drug Discovery & Development spoke with Susan Murphy, President of Molecular Devices, which works to enable high-throughput organoid research for life scientists.
Read full article.